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Abstract
OBJECTIVE: The objective of this systematic review is to determine whether or not Actemra
(tocilizumab) in combination with methotrexate is an effective treatment for rheumatoid arthritis
in patients who had an inadequate response to methotrexate alone. Previous studies have shown
other biologic agents and disease modifying antirheumatic drugs (DMARDs) to have some
efficacy in treating rheumatoid arthritis. However, tocilizumab is a newly approved FDA drug
and therefore, its efficacy in treating RA has yet to be determined.

KEYWORDS: rheumatoid arthritis, tocilizumab, Actemra, and methotrexate.
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INTRODUCTION
Rheumatoid arthritis (RA) is the most common inflammatory arthritis and currently
affects 1% of the population.1 It is predominantly a female condition, but it can also be seen in
males. This autoimmune disease is characterized by progressive joint inflammation and damage
that is symmetric in nature. Rheumatoid arthritis has a predilection for the small bones of the
hands and feet including the metacarpal phalanx (MCP), proximal interphalanx (PIP), and
metatarsal phalanx (MTP) but may also affect the wrists, elbows, knees, ankles, and cervical
spine.3 This disease spares the distal interphalanx (DIP) and the axial skeleton except the
cervical spine. The articular signs and symptoms of rheumatoid arthritis include morning
stiffness lasting greater than 1 hour, joint swelling and tenderness, and limitation of movement.3
Deformities of the hand that are characteristic of RA include swan neck and boutonniere
deformities. Extra-articular manifestations that may be seen are fever, fatigue, weight loss,
anemia, lymphadenopathy, scleritis, episcleritis, pericarditis, vasculitis, amyloidosis, and
osteoporosis.3
Aggressive treatment is required to treat the chronic and erosive nature of rheumatoid
arthritis that can eventually lead to joint destruction. The exact etiology of rheumatoid arthritis is
unknown, and it is mainly a clinical diagnosis with labs and radiographs used for confirmation.
Therefore, physician assistants and other health care providers in various fields including family
medicine, internal medicine, orthopedics, and rheumatology must be adept and prompt in
diagnosing and treating this condition. Rheumatoid factor and anti-CCP are positive in 70-80%
of patients.3 Joint space narrowing and joint erosions may be present on radiographs with joint
erosions indicating late disease and a worse prognosis.3
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Treatment for rheumatoid arthritis has targeted the inflammatory system with disease
modifying antirheumatic drugs (DMARDs) and biologic agents that target specific cytokines.
The most common DMARD used is methotrexate, which is the first line therapy.3 Examples of
other DMARDs are sulfasalazine and leflunomide. The biologic agents include etanercept,
infliximab, adalimumab, and abatacept. Corticosteroids and over-the-counter nonsteroidal antiinflammatory drugs (NSAIDs) may be used as adjuvant therapy.
The current treatments for rheumatoid arthritis target specific cytokines, including tumor
necrosis factor α (TNFα) and interleukin 1 (IL-1).1 However, an estimated 20-40% of patients
do not respond to these regimens even when combined with methotrexate.1 It has become
essential to search for other treatment regimens for rheumatoid arthritis. Tocilizumab (Actemra)
is a recent FDA approved drug that targets the cytokine, interleukin 6 (IL-6), which has been
shown to be increased in the synovial tissue in patients with RA.4 This cytokine causes
activation of monocytes, neutrophils, T cells, B cells, and osteoclasts, which are all substantially
involved in the initiation and progression of rheumatoid arthritis4. Targeting interleukin 6 offers
an alternative treatment regimen for those individuals whose rheumatoid arthritis has been
resistant to the current treatment modalities.
OBJECTIVE
The objective of this systematic review is to determine whether or not Actemra
(tocilizumab) in combination with methotrexate is an effective treatment for rheumatoid arthritis
in patients who had an inadequate response to methotrexate alone. Previous studies have shown
other biologic agents and disease modifying antirheumatic drugs (DMARDs) to have some
efficacy in treating rheumatoid arthritis. However, tocilizumab is a newly approved FDA drug
and therefore, its efficacy in treating RA has yet to be determined.
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METHODS
The three studies that are included in this review are double-blind randomized controlled
trials comparing tocilizumab plus methotrexate to a placebo plus methotrexate for the treatment
of rheumatoid arthritis. Tocilizumab was given as 2, 4 or 8 mg/kg in the Maini study and as 4 or
8 mg/kg in the Smolen and Emery studies. The study population was adult patients with active
rheumatoid arthritis who had an inadequate response to methotrexate. The reduction in the
number of swollen and tender joints was the outcome measured using the ACR20 response rate
as the primary efficacy endpoint and ACR50 and ACR70 response rates as secondary efficacy
endpoints.
These studies were found by the author using Ovid, MEDLINE, and Cochrane databases.
The key words rheumatoid arthritis, tocilizumab, Actemra, and methotrexate were used in the
literature searches to find English articles published in peer-reviewed articles dated 2006 to the
present. The articles were chosen if they were relevant, valid, and the outcomes of the studies
mattered to the patients (Patient Oriented Evidence that Matters or POEMS). The selected
studies were those that abided by the following set of criteria: POEM, randomized controlled
trial, a diagnosis of rheumatoid arthritis according to the American College of Rheumatology
revised criteria, active rheumatoid arthritis for 6 months or more, a swollen joint count of 6 or
more, and a tender joint count of 8 or more. The studies that did not meet all of these
requirements were excluded from this review. The statistics that are reported are p-values,
numbers needed to treat (NNT), relative risk reduction (RRR), absolute risk reduction (ARR),
control event rate (CER), and experimental event rate (EER). Table 1 shows the demographics
of the three studies included in this review.
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Table 1. Demographics of included studies
Study
Type
#
Age Inclusion Criteria
Pts (yrs)
Emery,
Double 499 >18 Active RA >6
2008
blind
months, swollen
(1)
RCT
joint count >6,
tender joint count
>8, CRP >1 or
ESR >28, treated
with MTX for
>12 weeks

Exclusion Criteria

WD

Interventions

Uncontrolled medical 568
conditions, other
inflammatory disease,
malignancy,
infection,
immunodeficiency,
Hgb <8.5,
leucopenia,
thrombocytopenia,
neutropenia,
abnormal LFTs,
triglycerides >10,
active TB, hepatitis
B, hepatitis C

Tocilizumab 4 or
8 mg/kg IV q 4
weeks plus
methotrexate
once weekly

Maini,
2006
(2)

Double 200
blind
RCT

>18

Active RA >6
months, swollen
joint count >6,
tender joint count
>6, CRP >1 or
ESR >28, showed
inadequate
response to MTX
during a
minimum of 6
months of therapy

Leucopenia,
neutropenia,
thrombocytopenia,
abnormal LFTs,
received DMARD
other than MTX
within 4 weeks prior
to study, received
anti-TNF agents
within 12 weeks or
leflunomide within 6
months of infusion of
study medication

29

Tocilizumab 2, 4,
or 8 mg/kg IV q 4
weeks plus
methotrexate
once weekly

Smolen,
2008
(3)

Double 623
blind
RCT

>18

Swollen joint
count >6, tender
joint count >8,
CRP >10 or ESR
>28, received
MTX for >12
weeks

Autoimmune
57
diseases, significant
systemic involvement
secondary to RA,
previous infection,
hepatitis B, hepatitis
C, recurrent herpes,
abnormal chest x-ray,
previous unsuccessful
treatment with antiTNF agents

Tocilizumab 4 or
8 mg/kg IV q 4
weeks plus
methotrexate
once weekly
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OUTCOMES MEASURED
The primary outcome measured in all three studies was the ACR20 response. This is a
scale established by the American College of Rheumatology. An ACR20 response requires a
patient to have a 20% reduction in the number of swollen and tender joints. In addition, a 20%
reduction must be seen in 3 out of 5 other parameters including physician global assessment of
disease, patient global assessment of disease, patient assessment of pain, C-reactive protein or
erythrocyte sedimentation rate, and degree of disability in Health Assessment Questionnaire
(HAQ) score. The parameter that will be the focus of this review is the number of swollen and
tender joints. Secondary endpoints that were measured include the ACR50 and ACR70 response
rates which require a 50% and 70% reduction in the number of tender and swollen joints,
respectively. The two studies by Smolen and Emery measured these outcomes at week 24 where
as Maini measured the same outcomes at week 16.
RESULTS
All three double-blind randomized controlled trials used the ACR20 response as the
primary efficacy endpoint. This endpoint was analyzed by intention to treat. In the Maini study,
participants received tocilizumab at 2, 4, or 8 mg/kg plus methotrexate or a placebo plus
methotrexate. In both the Smolen and Emery studies, participants received tocilizumab at 4 or 8
mg/kg plus methotrexate or a placebo plus methotrexate. All participants received tocilizumab
or a placebo every 4 weeks and methotrexate every week. In addition, folic acid was
administered weekly to each participant to minimize methotrexate-related toxicity. In order to be
included in each of these studies, participants were required to have moderate to severe active
RA for at least 6 months (defined as > 6 tender joints and > 6 swollen joints, an ESR > 28
mm/hr, and/or an CRP > 1 mg/dl) and to have had an inadequate response to methotrexate or
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another DMARD. The Smolen study had the largest number of participants with 623 enrolled
and 566 completing the study. 499 participants were enrolled in the Emery study with 418
completing the study. Lastly, the Maini study had 200 participants enrolled with 171 completing
the study.
The ACR20 response was used as the primary efficacy endpoint, which is defined by the
American College of Rheumatology as the number of participants with a 20% reduction in the
signs and symptoms of rheumatoid arthritis. Smolen and Emery measured the ACR20 response
at 24 weeks, where as Maini measured it at week 16.
Table 2. Percentage of participants who achieved an ACR20 response
Study
Placebo + MTX
Tocilizumab
Tocilizumab
(control group)
2 mg/kg + MTX
4 mg/kg + MTX
Smolen
26%
--48%
Emery

10.1%

---

41%
64%
Maini
MTX = Methotrexate, NR = Not Reported

Tocilizumab
8 mg/kg + MTX
59%

30.4%

50%

63%

74%

Table 2 shows the percentage of participants who achieved an ACR20 response at week 24 in the
Smolen and Emery studies and at week 16 in the Maini study. In all three studies, significantly
more participants receiving tocilizumab 8 mg/kg had achieved an ACR20 response compared to
other doses of tocilizumab as well as to a placebo with p-values < 0.001. Additionally, those
receiving 2 mg/kg or 4 mg/kg of tocilizumab achieved an ACR20 response that was significantly
more than those receiving a placebo. The p-values for the 4 mg/kg groups in the Smolen, Emery,
and Maini studies were < 0.001, <0.001, and <0.05 respectively. The p-value for the 2 mg/kg
group in the Maini study was <0.05.
Since all of the results were presented as dichotomous data, they were left in this form to
be analyzed. First, the control event rate (CER) and the experimental event rate were calculated.
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The CER is the percentage of participants who responded to the placebo plus methotrexate and
the EER is the percentage of participants who responded to the intervention (tocilizumab plus
methotrexate). The CER and EER could then be used to calculate the absolute benefit increase
(ABI) and the relative benefit increase (RBI). The ABI is the increase of a good event as the
result of tocilizumab plus MTX. The RBI is the proportional increase in the rates of good
outcomes between the experimental and control groups. The number needed to treat (NNT) was
then calculated by dividing the absolute risk reduction into 1. This result indicates the number of
patients with rheumatoid arthritis that need to be treated with tocilizumab plus methotrexate in
order to achieve an ACR20 response indicating a reduction in the number of swollen and tender
joints. Table 3 below shows the results of the dichotomous data analysis for each of the three
studies. In the Emery study, only 3 patients need to be treated in order to achieve one ACR20
response where as in both the Smolen and Maini studies, 4 patients need to be treated. However,
these numbers needed to treat are very similar, indicating similar results among the three studies.
Table 3. Treatment analysis for patients receiving tocilizumab plus methotrexate vs placebo plus
methotrexate for rheumatoid arthritis
Study
# completed
CER
EER
ABI
RBI
NNT
study
(placebo +
(8 mg/kg
MTX)
tocilizumab
+ MTX)
Smolen
566
26%
59%
33%
227%
4
Emery

418

10.1%

50%

39%

495%

3

Maini

171

41%

74%

33%

180%

4

CER = Control Event Rate, EER = Experimental Event Rate, ABI = Absolute Benefit Increase,
RBI = Relative Benefit Increase, NNT = Number Needed to Treat, NR = Not Reported
ACR50 and ACR70 response rates were the secondary efficacy end points of the studies and the
results are summarized in tables 4 and 5 respectively. These response rates are the percentage of
participants who had a 50% (ACR50) or 70% (ACR70) reduction in the signs and symptoms of
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rheumatoid arthritis. In the Maini study, only the 8 mg/kg group had statistically significant
achievement of both ACR50 and ACR70 responses when compared to methotrexate alone with a
p-value < 0.05. Emery showed a statistically significant achievement of ACR50 and ACR70
responses in the 8 mg/kg group with p-values of p< 0.001 and p = 0.001 respectively when
compared to the control group. For the 4 mg/kg group, only the ACR50 response was
statistically significant when compared to the control group with a p-value <0.001. Lastly, the
Smolen study demonstrated that significantly more participants in both tocilizumab groups had
ACR50 and ACR70 responses than those in the control group (p-value < 0.001).
Table 4. Percentage of participants who achieved an ACR50 response
Study
Placebo + MTX
Tocilizumab
Tocilizumab
(control group)
2 mg/kg + MTX
4 mg/kg + MTX
Smolen
11%
--31%

Tocilizumab
8 mg/kg + MTX
44%

Emery

3.8%

---

16.8%

28.8%

Maini

29%

32%

37%

53%

MTX = methotrexate
Table 5. Percentage of participants who achieved an ACR70 response
Study
Placebo + MTX
Tocilizumab
Tocilizumab
(control group)
2 mg/kg + MTX
4 mg/kg + MTX
Smolen
2%
--12%

Tocilizumab
8 mg/kg + MTX
22%

Emery

1.3%

---

5%

12.4%

Maini

16%

14%

12%

37%

MTX = methotrexate
DISCUSSION
Tocilizumab (Actemra) is a humanized monoclonal antibody that targets interleukin-6
(IL-6) and prevents it from binding to the interleukin-6 receptors on cell surfaces.2 This
mechanism of action is important because in recent research, interleukin-6 has been shown to be
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a key cytokine in the initiation and progression of joint inflammation and destruction. Tumor
necrosis factor α and interleukin-1 have been the cytokines targeted thus far with rheumatoid
arthritis therapies without maximum efficacy. Tocilizumab was approved in the United States by
the FDA on January 8, 2010 for the treatment of moderate to severe rheumatoid arthritis after an
inadequate response to methotrexate or other DMARD.5 The cost for tocilizumab is estimated to
be between $1,060 and $2,125 per month.5 Currently, there are no contraindications listed by the
manufacturer.6 However, fatal infections including tuberculosis and invasive fungal, bacterial,
viral, and protozoal infections are listed as a black box warning. It is important to note that most
of these infections are found in patients who are using immunosuppressive therapy
concurrently.6
There are minimal limitations to the three trials included in this systematic review. All
three studies can be termed valid for the following reasons. They were randomized controlled
trials, the outcomes were presented as dichotomous data, and the patients, clinicians, and study
workers were blinded to the treatment. Additionally, losses to follow-up were less than 20%
with the calculated numbers being 16.2% lost in the Emery study, 9.1% lost in the Smolen study,
and 16.7% lost in the Maini study. The initial sample size in the Maini study was small
compared to the number of participants in the Emery and Smolen studies, 200, 499, and 623
respectively. Therefore, the smaller sample size in the Maini study may have affected the
results.
CONCLUSION
The systematic review of the three randomized controlled studies indicates that
tocilizumab in combination with methotrexate is an effective treatment option for patients that
have had an inadequate response to methotrexate alone. Optimum doses of tocilizumab have
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been shown to be 4 mg/kg and 8 mg/kg. Dosing at 2 mg/kg was not proven to be statistically
significant compared to the control group in the Maini study. Doses higher than 8 mg/kg have
not been investigated and should therefore be avoided until further investigation is completed.
The 6 month time frame used in each of these studies seemed adequate to evaluate the efficacy
of tocilizumab, but future studies should incorporate observation of long term clinical
improvement and/or deterioration of patients’ rheumatoid arthritis. Additionally, only one of the
studies was conducted in Europe and North America so future studies are needed to assess the
efficacy of tocilizumab in patients with rheumatoid arthritis in the United States.

